Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

JCO Precis Oncol. 2024 Oct:8:e2400254. doi: 10.1200/PO.24.00254. Epub 2024 Oct 11.

Authors

Maria Fatteh^{1

2}, Jaime Wehr^{1

2}, Katerina Karaindrou^{1

2}, Rena R Xian^{2

3}, Christopher Gocke^{2

3}, Ming-Tseh Lin^{2

3}, Dana Petry^{1

2}, Kala Visvanathan^{1

2}, Rima Couzi^{1

2}, Cesar Santa Maria¹, Vered Stearns¹, Jessica J Tao^{1

2}, Valsamo Anagnostou^{1

2}, Jenna V Canzoniero^{1

2}; and the Johns Hopkins Molecular Tumor Board; Johns Hopkins Molecular Tumor Board

Affiliations

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
² The Johns Hopkins Molecular Tumor Board, Johns Hopkins University School of Medicine, Baltimore, MD.
³ Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD.

Abstract

Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.

Publication types

Case Reports

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Drug Resistance, Neoplasm* / genetics
Female
Humans
Mutation*
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

Poly(ADP-ribose) Polymerase Inhibitors

Grants and funding

U01 CA274631/CA/NCI NIH HHS/United States